Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1

Giulio Francolini, Mette S Thomsen, Esben Svitzer Yates, Carine Kirkove, Ingelise Jensen, Egil S. Blix, Claus Kamby, Mette Holck Nielsen, Mechthild Krause, Martin Berg, Ingvil Mjaaland, Andreas Schreiber, Unn miriam Kasti, Kristian Boye, Birgitte Vrou Offersen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Background and purpose: To report on a Quality assessment (QA) of Skagen Trial 1, exploring hypofractionation for breast cancer patients with indication for regional nodal radiotherapy. Material and methods: Deviations from protocol regarding target volume delineations and dose parameters (Dmin, Dmax, D98%, D95% and D2%) from randomly selected dose plans were assessed. Target volume delineation according to ESTRO guidelines was obtained through atlas based automated segmentation and centrally approved as gold standard (GS). Dice similarity scores (DSC) with original delineations were measured. Dose parameters measured in the two delineations were reported to assess their dosimetric outcome. Results: Assessment included 88 plans from 12 centres in 4 countries. DSC showed high agreement in contouring, 99% and 96% of the patients had a complete delineation of target volumes and organs at risk. No deviations in the dosimetric outcome were found in 76% of the patients, 82% and 95% of the patients had successful coverage of breast/chestwall and CTVn_L2-4-interpectoral. Dosimetric outcomes of original delineation and GS were comparable. Conclusions: QA showed high protocol compliance and adequate dose coverage in most patients. Inter-observer variability in contouring was low. Dose parameters were in harmony with protocol regardless original or GS segmentation.

OriginalsprogEngelsk
TidsskriftRadiotherapy & Oncology
Vol/bind123
Udgave nummer2
Sider (fra-til)282–287
ISSN0167-8140
DOI
StatusUdgivet - 2017

Fingeraftryk

Guideline Adherence
Observer Variation
Guidelines

Citer dette

Francolini, G., Thomsen, M. S., Yates, E. S., Kirkove, C., Jensen, I., Blix, E. S., ... Offersen, B. V. (2017). Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1. Radiotherapy & Oncology, 123(2), 282–287. https://doi.org/10.1016/j.radonc.2017.03.011
Francolini, Giulio ; Thomsen, Mette S ; Yates, Esben Svitzer ; Kirkove, Carine ; Jensen, Ingelise ; Blix, Egil S. ; Kamby, Claus ; Holck Nielsen, Mette ; Krause, Mechthild ; Berg, Martin ; Mjaaland, Ingvil ; Schreiber, Andreas ; Kasti, Unn miriam ; Boye, Kristian ; Offersen, Birgitte Vrou. / Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1. I: Radiotherapy & Oncology. 2017 ; Bind 123, Nr. 2. s. 282–287.
@article{07ae2df63ef24a46949f7aaa4ba9f424,
title = "Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1",
abstract = "Background and purpose: To report on a Quality assessment (QA) of Skagen Trial 1, exploring hypofractionation for breast cancer patients with indication for regional nodal radiotherapy. Material and methods: Deviations from protocol regarding target volume delineations and dose parameters (Dmin, Dmax, D98{\%}, D95{\%} and D2{\%}) from randomly selected dose plans were assessed. Target volume delineation according to ESTRO guidelines was obtained through atlas based automated segmentation and centrally approved as gold standard (GS). Dice similarity scores (DSC) with original delineations were measured. Dose parameters measured in the two delineations were reported to assess their dosimetric outcome. Results: Assessment included 88 plans from 12 centres in 4 countries. DSC showed high agreement in contouring, 99{\%} and 96{\%} of the patients had a complete delineation of target volumes and organs at risk. No deviations in the dosimetric outcome were found in 76{\%} of the patients, 82{\%} and 95{\%} of the patients had successful coverage of breast/chestwall and CTVn_L2-4-interpectoral. Dosimetric outcomes of original delineation and GS were comparable. Conclusions: QA showed high protocol compliance and adequate dose coverage in most patients. Inter-observer variability in contouring was low. Dose parameters were in harmony with protocol regardless original or GS segmentation.",
keywords = "Delineation, Quality assessment, Skagen Trial 1",
author = "Giulio Francolini and Thomsen, {Mette S} and Yates, {Esben Svitzer} and Carine Kirkove and Ingelise Jensen and Blix, {Egil S.} and Claus Kamby and {Holck Nielsen}, Mette and Mechthild Krause and Martin Berg and Ingvil Mjaaland and Andreas Schreiber and Kasti, {Unn miriam} and Kristian Boye and Offersen, {Birgitte Vrou}",
year = "2017",
doi = "10.1016/j.radonc.2017.03.011",
language = "English",
volume = "123",
pages = "282–287",
journal = "Radiotherapy & Oncology",
issn = "0167-8140",
publisher = "Elsevier",
number = "2",

}

Francolini, G, Thomsen, MS, Yates, ES, Kirkove, C, Jensen, I, Blix, ES, Kamby, C, Holck Nielsen, M, Krause, M, Berg, M, Mjaaland, I, Schreiber, A, Kasti, UM, Boye, K & Offersen, BV 2017, 'Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1', Radiotherapy & Oncology, bind 123, nr. 2, s. 282–287. https://doi.org/10.1016/j.radonc.2017.03.011

Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1. / Francolini, Giulio; Thomsen, Mette S; Yates, Esben Svitzer; Kirkove, Carine; Jensen, Ingelise; Blix, Egil S. ; Kamby, Claus; Holck Nielsen, Mette; Krause, Mechthild; Berg, Martin; Mjaaland, Ingvil ; Schreiber, Andreas; Kasti, Unn miriam; Boye, Kristian; Offersen, Birgitte Vrou.

I: Radiotherapy & Oncology, Bind 123, Nr. 2, 2017, s. 282–287.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1

AU - Francolini, Giulio

AU - Thomsen, Mette S

AU - Yates, Esben Svitzer

AU - Kirkove, Carine

AU - Jensen, Ingelise

AU - Blix, Egil S.

AU - Kamby, Claus

AU - Holck Nielsen, Mette

AU - Krause, Mechthild

AU - Berg, Martin

AU - Mjaaland, Ingvil

AU - Schreiber, Andreas

AU - Kasti, Unn miriam

AU - Boye, Kristian

AU - Offersen, Birgitte Vrou

PY - 2017

Y1 - 2017

N2 - Background and purpose: To report on a Quality assessment (QA) of Skagen Trial 1, exploring hypofractionation for breast cancer patients with indication for regional nodal radiotherapy. Material and methods: Deviations from protocol regarding target volume delineations and dose parameters (Dmin, Dmax, D98%, D95% and D2%) from randomly selected dose plans were assessed. Target volume delineation according to ESTRO guidelines was obtained through atlas based automated segmentation and centrally approved as gold standard (GS). Dice similarity scores (DSC) with original delineations were measured. Dose parameters measured in the two delineations were reported to assess their dosimetric outcome. Results: Assessment included 88 plans from 12 centres in 4 countries. DSC showed high agreement in contouring, 99% and 96% of the patients had a complete delineation of target volumes and organs at risk. No deviations in the dosimetric outcome were found in 76% of the patients, 82% and 95% of the patients had successful coverage of breast/chestwall and CTVn_L2-4-interpectoral. Dosimetric outcomes of original delineation and GS were comparable. Conclusions: QA showed high protocol compliance and adequate dose coverage in most patients. Inter-observer variability in contouring was low. Dose parameters were in harmony with protocol regardless original or GS segmentation.

AB - Background and purpose: To report on a Quality assessment (QA) of Skagen Trial 1, exploring hypofractionation for breast cancer patients with indication for regional nodal radiotherapy. Material and methods: Deviations from protocol regarding target volume delineations and dose parameters (Dmin, Dmax, D98%, D95% and D2%) from randomly selected dose plans were assessed. Target volume delineation according to ESTRO guidelines was obtained through atlas based automated segmentation and centrally approved as gold standard (GS). Dice similarity scores (DSC) with original delineations were measured. Dose parameters measured in the two delineations were reported to assess their dosimetric outcome. Results: Assessment included 88 plans from 12 centres in 4 countries. DSC showed high agreement in contouring, 99% and 96% of the patients had a complete delineation of target volumes and organs at risk. No deviations in the dosimetric outcome were found in 76% of the patients, 82% and 95% of the patients had successful coverage of breast/chestwall and CTVn_L2-4-interpectoral. Dosimetric outcomes of original delineation and GS were comparable. Conclusions: QA showed high protocol compliance and adequate dose coverage in most patients. Inter-observer variability in contouring was low. Dose parameters were in harmony with protocol regardless original or GS segmentation.

KW - Delineation

KW - Quality assessment

KW - Skagen Trial 1

U2 - 10.1016/j.radonc.2017.03.011

DO - 10.1016/j.radonc.2017.03.011

M3 - Journal article

C2 - 28351523

AN - SCOPUS:85016045058

VL - 123

SP - 282

EP - 287

JO - Radiotherapy & Oncology

JF - Radiotherapy & Oncology

SN - 0167-8140

IS - 2

ER -